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Abstract: It is well established that melatonin exerts antitumoral effects in many cancer 
types, mostly decreasing cell proliferation at low concentrations. On the other hand, 
induction of apoptosis by melatonin has been described in the last few years in some 
particular cancer types. The cytotoxic effect occurs after its administration at high 
concentrations, and the molecular pathways involved have been only partially determined. 
Moreover, a synergistic effect has been found in several cancer types when it is 
administered in combination with chemotherapeutic agents. In the present review, we will 
summarize published work on the pro-apoptotic effect of melatonin in cancer cells and the 
reported mechanisms involved in such action. We will also construct a hypothesis on how 
different cell signaling pathways may relate each other on account for such effect.  
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1. Introduction 
The natural indoleamine, melatonin, is known to regulate light/darkness responses in living 
organisms from all kingdoms. However, the therapeutic potential of melatonin goes beyond the 
treatment of jet lag or sleep disorders; this indole showing neuroprotective and antitumoral properties 
in many experimental conditions [1–6]. 
The antitumoral effects of melatonin are observed at many different levels. The alteration of 
melatonin circadian rhythm in professionals doing night shifts increases the incidence of some kinds of 
tumors [7,8]. Conversely, melatonin concentrations in plasma are affected in cancer patients [9].  
In experimental models of cancer, plasma concentrations of melatonin show oncostatic effects on 
tumors from a wide range of origins, by inhibiting tumor cell proliferation. Breast cancer is probably 
one of the most studied melatonin-sensitive tumors, and there are currently consolidated hypothesis 
explaining the intracellular signaling pathways involved in melatonin inhibition of breast cancer cell 
growth at plasma concentrations [10–12]. These data emphasize the possible importance of endogenous 
melatonin as an antitumoral agent. 
Melatonin antitumoral effects in experimental models of cancer have been mostly studied using 
concentrations of the indole that are similar to those found in plasma, within the nanomolar range. 
Plasma concentrations are usually referred to as “physiological”. However, higher concentrations of 
this indole have also shown interesting effects in multiple diseases and conditions, including cancer. 
Said concentrations range from micromolar to millimolar, and authors frequently refer to them as 
“pharmacological” concentrations, since they are higher than plasma concentrations. However,  
in our opinion, the terms “physiological” and “pharmacological” should be revised. The term 
“pharmacological” has somewhat acquired negative connotations. Reviewers often argue that these 
concentrations are not physiological and that their use for human therapies is unrealistic. Melatonin 
concentration in the extracellular space remains unknown, and therefore, micro- or milli-molar 
concentrations of melatonin in the cell culture media may well be physiological. Additionally, saliva, 
bile and cerebrospinal fluid show higher melatonin concentrations than plasma, indicating a 
compartmentalization of the hormone that could result in its accumulation at micro- or milli-molar 
concentrations in cells and tissues [13,14]. For these reasons, and until these questions are addressed, 
we believe that the term “high” is more accurate to refer to micro/millimolar levels of melatonin and 
has less negative connotations than the term “pharmacological”. We will use this nomenclature 
throughout the present review. 
Some cancer cells, such as androgen-independent prostate cancer cells or glioma cells, are 
insensitive to nanomolar concentrations of melatonin. However, their growth is inhibited by millimolar 
concentrations of the indole [15,16]. These data indicate that the oncostatic effects of melatonin could 
be extended to more cancer types by simply increasing its concentration. Furthermore, we and others 
have reported that high concentrations of melatonin induce apoptosis in certain types of cancer, such as 
Ewing’s sarcoma and most of types of hematologic cancer. However, the cytotoxic effect of melatonin 
seems to occur only in specific types of tumors and is not as extended as its oncostatic action. 
Melatonin’s cytotoxic effect in particular tumoral cells is counter-intuitive, since high concentrations 
of melatonin also protect normal cells against oxidative damage, preventing the modifications of DNA, 
lipids and proteins exposed to oxidants [17–19]. In fact, inhibition of cell proliferation by high 
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melatonin concentrations is, even in cancer cells, strongly associated with the antioxidant properties of 
the indole [16,20]. However, we and others have observed that high concentrations of melatonin enhance 
the effect of chemotherapeutic drugs, both in cultured cancer cells [21–31] and in vivo [32,33], 
suggesting that melatonin can be, in fact, also deleterious for cancer cells in particular conditions.  
While the oncostatic effects of melatonin at nanomolar concentrations have been extensively 
studied and the pathways involved are relatively well characterized, the mechanisms of action of high 
melatonin concentrations and their cytotoxic effects remain poorly understood. This review focuses on 
the antitumoral effects of melatonin at high concentrations, with special attention to its cytotoxic 
effects on particular types of tumoral cells. 
2. Pro-Apoptotic Effects of High Concentrations of Melatonin 
The antitumoral effects of melatonin can be classified as cytostatic or cytotoxic. While both low and 
high concentrations of melatonin are able to stop the proliferation of tumoral cells, the cytotoxicity is 
observed exclusively at high concentrations of the indole. The kind of effect and its potency, however, 
depends strongly on the type of cell and tumor.  
We have mentioned above that breast cancer cells are sensitive to plasma concentrations of 
melatonin and respond by stopping their proliferation [1,34]. Some cancer cells have little or no 
sensitivity to low, nanomolar concentrations of melatonin, but respond to higher concentrations by 
decreasing their proliferation markedly. While millimolar concentrations of this indole inhibit the 
proliferation of colon cancer cells, lower concentrations have no effect [35]. Nanomolar melatonin 
decreases the proliferation of ovarian CHO cells slightly (12%). However, at 1 millimolar, melatonin 
induces a striking decrease in their proliferation (50%) without inducing cytotoxicity [36]. Similarly, 
LNCaP human androgen-dependent prostate cancer cells show decreased proliferation (60%) after six 
days of treatment with melatonin 1 mM [15]. High, but not low, concentrations of melatonin also 
induce a decrease in the growth of the androgen-insensitive PC3 human prostate cancer cells, although 
not as markedly as androgen-dependent cells [15]. C6 rat glioma and A172 human glioblastoma cells 
do not respond to low concentrations of melatonin, but also stop proliferating without losing viability 
in the presence of millimolar concentrations of melatonin [16,37]. 
Cytotoxicity is not observed in any of the examples shown above nor, to the best of our knowledge, 
in any type of non-tumoral cell. For example, melatonin (100 µM) inhibits neural stem cell 
proliferation and promotes their differentiation [38]. Human umbilical vein endothelial cells 
(HUVECs) also stop their proliferation in the presence of high melatonin concentrations [39]. Primary 
cultures of hepatocytes show growth arrest in the presence of high melatonin concentrations, but no 
cytotoxicity, even at concentrations as high as 10 mM [40]. HT22 is a non-tumoral mouse 
hippocampal cell line that also shows a marked decrease in its growth only at millimolar 
concentrations of melatonin (Figure 1). HT22 cell viability remains unchanged even at 2 mM 
melatonin, this being the maximum concentration tested in our laboratory, due to solubility issues. 
A very restricted group of cancer cells show a cell death response after their treatment with high 
concentrations of melatonin, such cytotoxicity showing features corresponding to apoptosis (Figure 2). 
There are two main pathways to induce apoptosis, both of which seem to be involved, individually or 
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in combination, in melatonin-induced cell death: the extrinsic or death receptor pathway and the 
intrinsic or mitochondrial pathway (Figure 3).  
Figure 1. Melatonin effects on the hippocampal HT22 cell line. (A) Cells were incubated 
with several concentrations of melatonin. MTT reduction (which is proportional to the total 
number of cells) was determined after 24 h incubation. * p < 0.01 vs. all groups; (B) Cells 
were incubated with 1 mM melatonin for several time-points, and the MTT reduction was 
evaluated. * p < 0.01 vs. 4, 8 and 12 h incubation; (C) Cells were incubated with or without 
(control) 1 mM melatonin for 48 h and observed under phase contrast microscopy. The 
decrease of cell number without the increase of cellular debris is observed in cells treated 
with melatonin; (D) The decrease in total lactate dehydrogenase (LDH) (which is 
proportional to the total number of live cells) and no changes in the released LDH/total 
LDH ratio (which is proportional to the number of dead cells) was determined after 48 h of 
treatment with 1 mM melatonin. 
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Figure 2. Melatonin effects on Ewing’s sarcoma cell lines. (A) Several Ewing’s sarcoma 
cell lines were incubated with increasing concentrations of melatonin. MTT (which is 
proportional to the total number of cells) was determined after 72 h. Melatonin 
concentrations over 100 μM decreased MTT. * p < 0.05 vs. vehicle treated groups;  
(B) Total LDH (which is proportional to the total number of live cells) and the released 
LDH/total LDH ratio (which is proportional to the number of dead cells) were determined 
after 72 h of incubation with 1 mM melatonin. All four cell lines studied showed an 
increase in cell death; (C) Caspase 3 activity was evaluated after 48 of incubation with  
1 mM melatonin. It was increased in all four cell lines studied; (D) Electron microscope 
photographs of apoptosis induced by 1 mM melatonin in TC71 Ewing’s sarcoma after 
incubation for 72 h. The photograph on the left belongs to a non-treated TC71 cells.  
Bars: 1 μM. 
 
The extrinsic pathway is triggered by the binding of specific ligands from the TNF family (TNF, 
Fas ligand -Fas L-, TRAIL) to their receptors (death receptors: TNRF, Fas, Trail-R1, Trail-R2, DR3, 
DR6), which exist as trimers on the cell surface. The intracellular domain of death receptors (death 
domain), once activated by ligand binding, interacts with similar domains in particular adaptor 
molecules, bringing several of these molecules together and exposing their death effector domain 
(DED). The DED domain of adaptor molecules binds to the DED domain in caspase 8 monomers, 
resulting in dimmer formation and activation of this initiator caspase. The complex formed by the 
death receptor, the adaptor protein and the procaspase 8 is called the death-inducing signaling complex 
(DISC). Activated caspase 8 then cleaves executioner caspases (3, 6 and 7), which will act on their 
substrates, giving place to the morphological and biochemical features of apoptosis, or activates other 
proteins that allow crosstalk with the intrinsic pathway of apoptosis. 
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Figure 3. General view of the extrinsic and the intrinsic pathways of apoptosis. * Affected 
by melatonin. 
 
The intrinsic pathway of apoptosis relies on the disruption and permeabilization of the 
mitochondrial outer membrane (MOMP), which is followed by cytochrome c release and activation of 
the apoptosome. Activation by different stimuli of the pro-apoptotic members of the Bcl-2 family, such 
as Bax and Bak, are able to trigger MOMP. Such activation is controlled by other Bcl-2 family 
proteins (also pro-apoptotic), such as the activator BH3-only protein, Bim, or the de-repressor  
BH3-only protein, Bad. Anti-apoptotic proteins of the same family (Bcl-2, Bcl-XL and more) bind 
activator proteins in the absence of apoptotic stimuli, tightly regulating their activity and avoiding 
MOMP. Once MOMP occurs, cytochrome c is released into the cytosol and binds apoptotic protease 
activating factor 1 (APAF-1), which changes its conformation and exposes its oligomerization domain. 
Seven APAF-1 molecules bind to each other and form the apoptosome. This structure recruits 
procaspase-9 molecules and activates them, leading to the cleavage and subsequent activation of 
executioner caspases (-3, -6 and -7). As we mentioned above, the extrinsic pathway of apoptosis may 
engage the intrinsic one by caspase-8-mediated activation of proteins, such as the activator BH3-only 
protein Bid, which in turn activates Bax and Bak [41]. 
Hematological tumors are the best studied and the ones that present the most uniform results 
concerning the apoptotic effect by melatonin. Trubiani et al. [42] described the activation of caspase-3 
after treatment with 2 mM melatonin in a cell line of Burkitt lymphoma (RAMOS). Such treatment 
also induced a decrease in the levels of the anti-apoptotic protein, Bcl-2, an increase in cytochrome c 
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levels in the cytoplasm and an increase in mitochondria depolarization, all of them indicators of 
apoptotic cell death. Acute myeloid leukemia HL60 cells also show an increase in activated caspase-9 
and caspase-3, the levels of the pro-apoptotic protein, Bax, and of cytochrome c released to the 
cytoplasm, as well as a decrease in Bcl-2 levels [43]. Similar results were observed later by  
Bejarano et al. [44,45] in acute myeloid leukemia (HL60) and chronic myeloid leukemia (K562) cells. 
The data from these three groups suggest that high concentrations of melatonin activate the intrinsic 
apoptotic pathway in hematologic cancer cells. However, they did not explore any parameter of the 
extrinsic pathway, and therefore, its involvement in melatonin’s cytotoxic effect cannot be ruled out. 
We reported induction of apoptosis by 1 mM melatonin in acute myeloid leukemia (HL60), chronic 
myeloid leukemia (K562), Burkitt lymphoma (CA-46, RAMOS and RAJI) and acute lymphoid 
leukemia (RHE) cells [46]. Parameters from both the intrinsic and extrinsic apoptosis pathways were 
studied, showing an increase in the activation of caspases 3, 7 (executor caspases), 8 (initiator caspase 
of the extrinsic pathway) and 9 (initiator caspase of intrinsic pathway). It is noticeable that the increase 
in caspase-8 activity was much more pronounced than the increase in caspase-9 activity. The levels of 
activated proapoptotic protein, Bid, which is activated by caspase-8 and involved in the activation of 
the mitochondrial pathway of apoptosis, were also increased. Furthermore, the expression of both Fas 
and its ligand, FasL, limiting upstream factors of the extrinsic pathway, was highly increased after 
melatonin treatment. Recent studies on lymphoid cancer cells [47] showed activation of both caspases, 
8 and 9, in two of the cell lines studied (RAMOS and SU-DHL-4), while only caspase 9 was activated 
in DoHH2 and JURKAT cells. 
These data strongly support that both the intrinsic and extrinsic pathways of apoptosis are activated 
by millimolar concentrations of melatonin in hematological cancer cells. Interestingly, melatonin 
sensitizes human glioma cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced cell death, 
cells that otherwise respond to melatonin by stopping their growth [26]. Further studies should be done 
to elucidate the interplay between these two apoptotic pathways in cancer cells upon melatonin 
treatment, since different pathways may be involved in the effect on different types of cancer or even 
on different cell lines. 
A cytotoxic effect by millimolar concentrations of melatonin was also found in Ewing’s sarcoma 
cells, although not in other types of sarcoma [37,48]. Although we originally assumed that SK-N-MC 
cells were neuroblastoma cells, they are currently considered as Ewing sarcoma cells, based on the 
translocation that gives rise to the Ews-Fli1 protein and other molecular features. Later on [49], we 
further characterized this cytotoxic effect as apoptosis and associated it to the activation of the extrinsic 
pathway (i.e., the increase in the expression of Fas/Fas L and the proapoptotic gene, Bcl-Xs, and 
caspase-8 activation). Results were confirmed in various Ewing sarcoma cell lines. 
Other cancer types seem to die in the presence of high concentrations of melatonin, but the results 
are more controversial. One of the first reports on melatonin-induced cell death was by  
Winczyk et al. [50], who reported induction of apoptosis by melatonin in colon cancer in vivo. 
However, their results have not been confirmed by other laboratories, and colon cancer cells seem to 
respond to high melatonin concentrations mainly by reducing their proliferation [22,35].  
Ozdemir et al. [51] showed inhibition of cell proliferation, but not apoptosis, after the treatment of 
HepG2 liver cancer cells with melatonin 1 mM. However, Martín-Renedo et al. [52] showed apoptosis 
induced by 1 mM of the indole in the same cell line. They found cell death accompanied by activation 
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of caspases 8, 9 and 3; and an increase in the levels of the proapoptotic protein, Bax, and cytosolic 
cytochrome c. They did not analyze Fas/Fas L expression or other cell death receptors or ligands, but 
their results clearly involved the extrinsic apoptotic pathway. Recently, the same group showed that 
melatonin upregulates the proapoptotic protein, Bim, through the increase of FoxO3a transcriptional 
activity in the same cells [53].  
Results on prostate cancer cells are also controversial. Joo and Yoo [54] showed induction of 
apoptosis by melatonin 1 mM in androgen-dependent LNCaP prostate cancer cells, as determined by 
the binding of annexin-V. Later on, the same group [55] showed activation of caspase 8 accompanied 
by an increase in the levels of Bax and a decrease in the levels of the anti-apoptotic protein, Bcl-2. 
However, these results contradict others previously reported by Sainz et al. [15] in the same cell line. 
Even though Sainz et al. also found an important MTT reduction in the same cell line after treatment 
with 1 mM melatonin, they found no decrease in cell viability by means of trypan blue assays, 
suggesting that such a decrease in cell number is due to a cytostatic and not a cytotoxic action  
of melatonin.  
A decrease in cell number together with an increase in caspase 3 activity were found by  
Gonzalez et al. [56] in a rat pancreas cancer cell line (AR42J) treated with millimolar concentrations of 
melatonin. These results remain to be confirmed in other pancreatic cancer cells and by other groups, 
but, given the deadly nature of pancreatic cancer, we believe further studies should definitely be 
carried out in this direction.  
Other tumoral cells show no response whatsoever to either low or high melatonin concentrations. 
For example, Sanchez-Sanchez et al. [37] found no changes in cell proliferation or viability in A549 
human pulmonary adenocarcinoma cells. However, due to the general tendency to publish only 
positive results, it is not easy to find studies where non-sensitive cells are reported. While our 
experience is that most cells respond to at least high concentrations of melatonin, the number of  
non-sensitive cells could be greatly underrated, due to the lack of published evidence. Such cells could 
be extremely useful to define the molecular determinants of melatonin effects, which should obviously 
be present in sensitive cells and absent in non-sensitive cells.  
In summary, melatonin-induced apoptosis only occurs at high concentrations of the indole and only 
in specific cancer types. Both the extrinsic and intrinsic pathways of apoptosis can be activated by 
melatonin, but little is still know about the exact contribution of each pathway to effects of the indole.  
3. Mechanisms of Action Involved in the Pro-Apoptotic Effect of High Concentrations  
of Melatonin 
One of the greater difficulties found in mechanistic studies at cellular and molecular levels are the 
constant intersection and crosstalk between signaling pathways, since most proteins are involved in 
several of them. It took years to explain the intracellular signaling pathways involved in the cytostatic 
effects of low concentrations of melatonin, which works mainly via its membrane receptors [12]. It is 
therefore not surprising that the mechanisms underlying the pro-apoptotic effects by high 
concentrations of melatonin—much higher than it is necessary to bind its receptors—remain to be 
unraveled after less than a decade of efforts. 
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3.1. Melatonin-Induced Apoptosis Is Associated with an Early Increase of Reactive Oxygen  
Species (ROS)  
As melatonin has antioxidant properties at high concentrations, several reports on melatonin 
apoptotic effects studied the oxidative status of cells upon treatment with the indole. Opposite to what 
was expected, researchers found that there is an early increase in oxidative stress in those cancer cells, 
where melatonin induces apoptosis, besides the late increase of intracellular oxidants associated to 
apoptosis itself. Osseni et al. [57] reported that only 45 min after treatment with melatonin at 
concentrations higher than 100 μM, there was an increase in the production of reactive oxygen species 
(ROS) in HepG2 cells. This increase was concomitant to a loss of cell viability, although they did not 
analyze whether there was actually apoptosis. Wolfler et al. [58] also found an increment in ROS 
production in Jurkat cells after less than one hour of treatment with melatonin (500 μM–2.5 mM). 
Such an effect was prevented by antioxidants (i.e., glutathione or trolox). The observed increase in 
ROS production induced by melatonin corresponded with a potentiation of later ROS increments and  
FasL-induced toxicity. However, they did not analyze the possible pro-apoptotic effect of melatonin by 
itself. Later on, Buyukavci et al. [59] found a correlation between the increase in ROS production and 
the induction of apoptosis by melatonin in several cell lines of hematological cancer. However, they 
used very early points to evaluate apoptosis, and we think their results would be even more 
pronounced if they used longer time points. Also, using cell lines of hematological cancer (AML HL60 
cells and CML K562 cells), Bejarano et al. [45] found that the increase in ROS production two hours 
after treatment with 1 mM melatonin corresponded to the decrease in cell viability and the activation  
of caspases 9 and 3. All of these changes were prevented by antioxidants (N-acetylcysteine, trolox, 
catalase or glutathione). Casado-Zapico et al. [46] showed an increase in ROS production previous to 
various apoptosis-related events analyzed in AML (HL60), CML (K562) and Burkitt (CA46) cell lines 
treated with 1 mM melatonin. More specifically, we observed an increase in the levels of death 
receptors and their ligands and activation of caspases from both the extrinsic and the intrinsic 
pathways. We reported similar results [49] in many Ewing sarcoma cell lines, also showing that 
additional treatment with antioxidants prevented ROS production and the decrease in cell viability. 
ROS form part of several signaling pathways activated by intra- or extra-cellular stimuli.  
At low levels, they can induce an increase in cell proliferation; while at high levels, they can induce 
apoptosis [60]. The role of ROS in apoptosis can follow different pathways, even in the same cell  
type [61]. First, ROS can induce apoptosis through the mitochondrial pathway, by interacting with 
proteins of the mitochondrial permeability transition complex [62]. Oxidative modification of such a 
complex can collapse the mitochondrial membrane potential and trigger the translocation of Bax and 
Bad pro-apoptotic proteins and the release of cytochrome c to the cytosol [63]. This is consistent with 
the observations by us and others in cancer cells that are sensitive to melatonin, particularly in liver 
cancer cells [52,57], acute myeloid leukemia cells [43,44,46] and Burkitt lymphoma cells [42,46].  
ROS can also activate the ASK/JNK signaling pathway and drive cells to apoptosis. It has been 
previously proved that the Trx1/ASK1 complex works as a redox sensor. When Trx1 is reduced, it 
prevents ASK1 activation and the apoptotic cascade [64]. On the other hand, in an oxidized 
environment with high ROS levels, Trx1 splits from the complex and allows ASK1 activation. ASK1 
then oligomerizes and promotes the formation of a complex with ASK2 and TRAFF2/6, which in turn 
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activates JNK and p38 [65]. Translocation of activated JNK to the nucleus promotes the expression of 
pro-apoptotic proteins, such as TNF alpha, FasL or Bak, and, consequently, the extrinsic apoptotic 
pathway [66]. On the other hand, JNK translocation to the mitochondria promotes cytochrome c 
release and, consequently, the intrinsic apoptotic pathway [67]. Although this pathway still has not 
been analyzed systematically in all cell lines where high concentrations of melatonin induce apoptosis, 
there is evidence indicating that JNK and p38 activation could be involved in melatonin-induced 
apoptosis, at least in some cancer cell types. Martin Renedo et al. [52] found an increase in the 
activation of JNK 1, 2 and 3 and p38 after the treatment of liver cancer cells with 1 mM melatonin. 
The activation of these kinases was accompanied by an increase in the levels/activity of p53, p21 and 
caspases 8, 9 and 3, as well as by cytochrome c release. Joo and Yoo [54] observed JNK and p38 
activation by 1 mM melatonin in LNCaP androgen-dependent prostate cancer cells. Inhibitors of these 
kinases prevented melatonin-induced cell death. Later on, they also demonstrated that the activation of 
these kinases was responsible for the increment in p21, p27 and p53 levels [55]. Both, leukemia and 
Ewing’s sarcoma cell lines show Fas L expression increase [46,49], which could be also related to the 
activation of this pathway by ROS, although JNK activation was not analyzed in these reports. A summary 
of the possible ROS-related pathways in the pro-apoptotic effect of melatonin is represented in Figure 4. 
Figure 4. Roles of ROS in apoptosis. * Affected by melatonin. 
 
3.2. The Early Increase of ROS Production Determines if Cancer Cells Die or Stop Proliferating in 
Response to Melatonin  
The data mentioned above suggest that the increase in ROS production is related to the  
pro-apoptotic effect of high concentrations of melatonin in cancer cells. We analyzed several 
parameters related to the intracellular redox state in a recent study [37], comparing cancer cell lines 
that die by apoptosis upon treatment with melatonin, cancer cells that decrease their proliferation in the 
same conditions and cancer cells that are not sensitive to melatonin. Intracellular levels of ROS 
increased early in cells that died by apoptosis, decreased after 48 h in cells that diminished their 
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proliferation and did not change in non-sensitive cells. Results on intracellular glutathione (GSH) were 
consistent with ROS levels in all cell lines. Cells that die by apoptosis showed decreased GSH levels; 
cells that stop proliferating showed increased GSH levels; and non-sensitive cells did not present any 
change. Variations in GSH levels occurred sometime after ROS levels changed, indicating that such 
variations are not the cause of ROS production, but probably a consequence of it. Finally, cells 
undergoing apoptosis presented decreased expression of antioxidant enzyme expression, probably as a 
consequence of the increase in ROS production, although they recover after 48 h of treatment. The 
opposite occurred in cells that decrease their proliferation in response to melatonin, and no changes 
were found in non-sensitive cells. Administration of antioxidants prevented melatonin-induced 
apoptosis, while hydrogen peroxide enhanced it. It seems, therefore, that the induction of apoptosis by 
high concentrations of melatonin in sensitive cancer cells is related to the increase in ROS levels and, given 
the early appearance of such phenomenon, it is likely to be a key factor in melatonin-induced cell death. 
3.3. The Reduction in Intracellular GSH Levels Could also Be Involved in the Pro-Apoptotic Effect  
of Melatonin 
While melatonin increases GSH levels in many cell types, both normal and tumoral, it produces the 
opposite effect in cells that undergo apoptosis. The decrease in intracellular GSH levels could be due 
to its oxidation by ROS, but also to its escape out of the cell [68]. It has been found in other cell types 
that -glutamyl transferase catalyzes the hydrolysis of extracellular GSH and, thus, induces the release 
of intracellular GSH reservoirs [69]. FasL also induces the release of cellular GSH in lymphoid cells, 
which is essential for FasL-dependent apoptosis [68]. These authors also observe that the increase in 
ROS levels is a side effect, rather than an event necessary for apoptosis. A decrease in intracellular 
GSH levels could also be due to de novo reduction of its synthesis. An arrest in GSH synthesis induces 
a type of apoptosis dependent on activation of protein kinase C (PKC) [70], while a decrease in GSH 
levels due to its release to the extracellular medium induces JNK-dependent apoptosis [71]. Although 
the decrease in GSH levels seems to be secondary to elevated ROS production in the case of 
melatonin-induced apoptosis [37], the involvement of GSH in melatonin cytotoxic effects deserves 
deeper study. GSH depletion by high concentrations of melatonin was reported by Albertini et al. [72] in 
U937 human leukemia cells, although these authors did not study whether melatonin also induced cell 
death. Casado-Zapico et al. [46] found Akt activation (a protein kinase downstream PKC) to be 
involved in melatonin-induced apoptosis in hematological cancer cell lines. Interestingly, melatonin 
sensitizes human glioblastoma cells to TRAIL-induced cell death by a pathway involving PKC and 
Akt [26]. JNK activation by melatonin has been found in liver cancer cells and androgen-dependent 
prostate cancer cells [52,54]. However, JNK is sensitive to redox changes, and its activation could 
therefore be triggered by the increase in ROS production. In summary, we believe further studies 
should be carried out in order to elucidate the exact role of ROS, GSH and apoptotic pathways in 
melatonin-induced cancer cell death. 
4. Conclusions  
Current evidence indicates that alterations of the intracellular redox state play a key role in the 
effects of high concentrations of melatonin in cancer cells, reducing conditions being associated with a 
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decrease in cell proliferation and oxidative conditions with apoptosis. The last data may be in conflict 
with the fact that high concentrations of melatonin show clear antioxidant properties. Furthermore, 
unlike other antioxidants, such as vitamins C or E, melatonin oxidation results in metabolites that still 
possess antioxidant properties [73–78]. Thus, the key question is: why are ROS elevated in some 
cancer cells upon their treatment with high concentrations of melatonin? We believe that a primary 
pro-oxidant effect of this indole could be ruled out, bearing in mind the data exposed above and the 
fact that this increase in ROS is not a general fact, but an exception. A fact to be considered is that the 
metabolism of cancer and normal cells shows numerous differences. Metabolism can also differ 
between different types of cancer. However, these are only speculations, and the actual explanation 
remains to be found. We believe that addressing this question is essential to understand the 
mechanisms involved in the antitumoral apoptotic effects of melatonin and that it will be a major 
challenge in the field for the next few years. The fruits of such efforts could contribute toward 
improving therapies for at least some particular types of cancer. 
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